• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

I Wouldn't Go 'All In' on Tilray, But Here's How I'd Trade It

Tilray is okay in my book for speculation.
By STEPHEN GUILFOYLE
Apr 06, 2022 | 10:50 AM EDT
Stocks quotes in this article: TLRY, AMZN

Tuesday morning, after the stock spiked in late March and then suffered five consecutive "down" days, Tilray Brands (TLRY) released the firm's fiscal third quarter financial results. Tilray posted GAAP EPS of $0.09 on revenue of $151.87M. The bottom line number crushed expectations for a net loss, while the top line result fell short of expectations despite year over year growth of 22.6%. A year ago, Tilray posted a GAAP EPS loss of $1.03 per share. Gross margin increased from 25% a year ago to 26% as gross profit itself increased 31% to $40M.

Net income totaled $52.5M, with adjusted EBITDA of $10.1M for a twelfth consecutive quarter of positive adjusted EBITDA. There is a catch though. These results include net non-operating income of $72.719M, compared to net non-operating expense of $220.34M for the year ago period.

Why The Recent Volatility?

Last week the House of Representatives passed the Marijuana Opportunity Reinvestment and Expungement (MORE) Act in a 220-204 vote. Provisions inside the bill include decriminalizing marijuana at the federal level by removing it from the list of controlled substances and removing any criminal penalties for those who make, distribute, or possess marijuana. This bill, if passed into law, would impose a federal tax on marijuana sales with proceeds funding programs for substance abuse treatment and legal counseling to aid communities negatively impacted by the war on drugs.

There is, however, no sure path to passage in the US Senate, as there were only three Republicans among the 220 "yea" votes in the House, and half of the Senate is Republican. Additionally, New York Senator Chuck Schumer, a Democrat, may not be a supporter of this bill, as he has some ideas of his own regarding federal legalization.

Net Revenue by Operating Segment

Distribution generated sales of $62.532M, down 11%.

Cannabis produced sales of $55.045M, up 31.9%.

Beverage Alcohol made sales of $19.597M, up 64.1%.

Wellness provided sales of $14.697M, with no year ago comparison.

Net Cannabis Revenue by Market Channel

Canadian Adult-Use generated sales of $43.504M, down 9.5%.

International produced sales of $15.82M, up from $347K.

Canadian Medical Use made sales of $7.05M, up 18.9%.

Wholesale provided sales of $2.804M, up 111.3%.

Excise taxes increased 1.1% to $14.133M

Notes

- Cost synergies from the Aphria acquisition came to $76M achieved on a run-rate basis to date. The firm expects to reach its $80M synergy target by the end of May, which will be five months early. The firm also expects to generate an additional $20M in synergies in fiscal 2023.

- Tilray remains number one in Canadian cannabis market share.

- Tilray has captured a rough 20% share of the German medical cannabis market. Germany is Europe's largest market for medical-use cannabis, and is expected to be a large market for recreational use once legalized.

- Tilray's Manitoba Harvest unit has launched its Hemp+ Macha and Hemp+ Supergreens powders exclusively at over 300 Whole Foods Markets (AMZN) locations across North America. The products are expected to land on shelves this month throughout the US and Canada.

Balance Sheet

As of February 28th, Tilray had a net cash position of $279.2M, down significantly over nine months' time, but up from a year ago. Accounts receivable and inventories have grown but only small. This leaves current assets at $695,8M. Total liabilities amount to $282.4M, which is also down significantly from nine months ago. Tilray stands with a current ratio of 2.46, which is comforting.

Total assets add up to $5.819B. However, nearly half of that comes from the entry for "goodwill." Readers know how much I love that. When adding what the firm refers to as "intangible assets" to "goodwill", non-definable assets comprise a rough 75% of total assets. Doesn't that seem a little bit ridiculous to you?

Total liabilities less equity runs to $1.158B, so assets dwarf liabilities whether or not the entry for goodwill is downsized. Even completely excluding the entries for both goodwill and intangible assets (yes, I know that goodwill is an intangible asset), assets still outweigh liabilities. All that said, I very reluctantly give Tilray's balance sheet a passing grade, but I do not love it.

Long-term debt remains a work in progress and the firm has been working on its reduction. Pure long-term debt is down to $121.2M, Lease liabilities are down to $16.2M, and convertible debentures are down to $501M.

My Thoughts

Tilray is okay in my book for speculation.

The variety in products helps. The deal with Whole Foods helps. The firm is clearly putting in the work to reign in the liability side of the balance sheet. I wouldn't go "all in" on Tilray or any of the existing cannabis stocks based purely on the hope that the Senate passes some form of federal cannabis legalization. I do think however, this name could be okay, at this level for a trade. By the way, as of mid-March... 14% of the entire float was held in short positions.

Readers will see that TLRY has been engaged in an attempt to break out of trend for several days now, but has so far failed to complete that move. It would be my preference to wait for confirmation of a take and hold of that upper trend line prior to allocating capital toward equity. Once support is established, the likeliest target would in my opinion, be the 200 day SMA, currently $10.24.

(Amazon is a holding in the Action Alerts PLUS member club. Want to be alerted before AAP buys or sells AMZN? Learn more now.)

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Stephen Guilfoyle had no position in the securities mentioned.

TAGS: Earnings | Investing | Stocks | Technical Analysis | Trading | Marijuana | Cannabis

More from Stocks

The Chasing Slows on Wall Street

James "Rev Shark" DePorre
Mar 24, 2023 4:34 PM EDT

After Deutsche Bank shakes up investors, market cools a bit, which might be a healthy development.

Stay Away From These Types of Stocks, They're Radioactive

Jim Collins
Mar 24, 2023 2:35 PM EDT

Here's what you're better off buying. I certainly have.

GE Looks Poised for a Pullback: How to Trade It Now

Bruce Kamich
Mar 24, 2023 1:45 PM EDT

The shares stopped short of my price targets.

It's Not Whether the Next Shoe Will Drop, But Where and When

Bret Jensen
Mar 24, 2023 11:30 AM EDT

A few months of anxiety likely lies ahead of us, and caution remains the watchword of the day.

The Good, Bad and Ugly: What's Happening and What Investors Need to Do

Stephen Guilfoyle
Mar 24, 2023 10:45 AM EDT

Right now I have more in cash, or equivalents, than in equities. Ever hear of a Wall Street guy saying that before?

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • 05:00 PM EDT CHRIS VERSACE

    AAP Podcast on the Fed Decision!

    Listen here!
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login